AKUS:NSD-Akouos, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 17.33

Change

-1.42 (-7.57)%

Market Cap

USD 0.64B

Volume

0.55M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+4.19 (+2.02%)

USD54.02B 20.19 15.08
MRNA Moderna, Inc

-0.11 (-0.08%)

USD52.89B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

+12.19 (+2.71%)

USD48.14B 14.72 11.87
ALXN Alexion Pharmaceuticals, Inc

+1.64 (+1.10%)

USD32.70B 54.58 32.28
BGNE BeiGene, Ltd

+12.06 (+4.17%)

USD27.37B N/A N/A
SGEN Seagen Inc

+3.90 (+2.68%)

USD26.35B 43.16 37.70
RPRX Royalty Pharma plc

+0.20 (+0.47%)

USD25.71B 22.60 14.17
BNTX BioNTech SE

+1.05 (+1.10%)

USD22.91B -99,999.99 N/A
GMAB Genmab A/S

+0.83 (+2.68%)

USD20.42B 26.59 3.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AKUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.61% 22% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.61% 22% F 12% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.64B 62% D- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 85% B 94% A
Price/Book Ratio 2.18 85% B 63% D
Price / Cash Flow Ratio -33.04 85% B 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 119.33% 98% A+ 99% A+
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 17.17 2% F 1% F
Short Percent 8.14% 36% F 24% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector